ATAI Valuation

ATAI Life Sciences NV

Add to Watchlist

Advanced Chart

4.580

-0.07(-1.505%)1D

Overview
Forecast
Valuation
Earnings

ATAI Relative Valuation

ATAI's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ATAI is overvalued; if below, it's undervalued.

Historical Valuation

ATAI Life Sciences NV (ATAI) is now in the Overvalued zone, suggesting that its current forward PS ratio of 5888.84 is considered Overvalued compared with the five-year average of -4.69. The fair price of ATAI Life Sciences NV (ATAI) is between 0.75 to 2.56 according to relative valuation methord. Compared to the current price of 4.58 USD , ATAI Life Sciences NV is Overvalued By 78.83%.

Relative Value

Fair Zone

0.75-2.56

Current Price：4.58

78.83%

Overvalued

-9.01

Trailing

Forward

-7.95

EV/EBITDA

ATAI Life Sciences NV. (ATAI) has a current EV/EBITDA of -7.95. The 5-year average EV/EBITDA is -3.50. The thresholds are as follows: Strongly Undervalued below -14.13, Undervalued between -14.13 and -8.82, Fairly Valued between 1.82 and -8.82, Overvalued between 1.82 and 7.14, and Strongly Overvalued above 7.14. The current Forward EV/EBITDA of -7.95 falls within the Historic Trend Line -Fairly Valued range.

-8.24

EV/EBIT

ATAI Life Sciences NV. (ATAI) has a current EV/EBIT of -8.24. The 5-year average EV/EBIT is -2.87. The thresholds are as follows: Strongly Undervalued below -10.30, Undervalued between -10.30 and -6.58, Fairly Valued between 0.85 and -6.58, Overvalued between 0.85 and 4.57, and Strongly Overvalued above 4.57. The current Forward EV/EBIT of -8.24 falls within the Undervalued range.

5888.84

ATAI Life Sciences NV. (ATAI) has a current PS of 5888.84. The 5-year average PS is 25324.84. The thresholds are as follows: Strongly Undervalued below -94988.86, Undervalued between -94988.86 and -34832.01, Fairly Valued between 85481.70 and -34832.01, Overvalued between 85481.70 and 145638.55, and Strongly Overvalued above 145638.55. The current Forward PS of 5888.84 falls within the Historic Trend Line -Fairly Valued range.

-10.56

P/OCF

ATAI Life Sciences NV. (ATAI) has a current P/OCF of -10.56. The 5-year average P/OCF is -6.05. The thresholds are as follows: Strongly Undervalued below -18.39, Undervalued between -18.39 and -12.22, Fairly Valued between 0.12 and -12.22, Overvalued between 0.12 and 6.30, and Strongly Overvalued above 6.30. The current Forward P/OCF of -10.56 falls within the Historic Trend Line -Fairly Valued range.

-9.80

P/FCF

ATAI Life Sciences NV. (ATAI) has a current P/FCF of -9.80. The 5-year average P/FCF is -6.08. The thresholds are as follows: Strongly Undervalued below -19.18, Undervalued between -19.18 and -12.63, Fairly Valued between 0.47 and -12.63, Overvalued between 0.47 and 7.02, and Strongly Overvalued above 7.02. The current Forward P/FCF of -9.80 falls within the Historic Trend Line -Fairly Valued range.

ATAI Life Sciences NV (ATAI) has a current Price-to-Book (P/B) ratio of 6.76. Compared to its 3-year average P/B ratio of 1.68 , the current P/B ratio is approximately 302.64% higher. Relative to its 5-year average P/B ratio of 2.30, the current P/B ratio is about 193.70% higher. ATAI Life Sciences NV (ATAI) has a Forward Free Cash Flow (FCF) yield of approximately -7.82%. Compared to its 3-year average FCF yield of -30.45%, the current FCF yield is approximately -74.34% lower. Relative to its 5-year average FCF yield of -23.52% , the current FCF yield is about -66.77% lower.

6.76

P/B

Median3y

1.68

Median5y

2.30

-7.82

FCF Yield

Median3y

-30.45

Median5y

-23.52

Competitors Valuation Multiple

The average P/S ratio for ATAI's competitors is 3210.79, providing a benchmark for relative valuation. ATAI Life Sciences NV Corp (ATAI) exhibits a P/S ratio of 5888.84, which is 83.41% above the industry average. Given its robust revenue growth of 163.37%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

ATAI.O

ATAI Life Sciences NV

Oric Pharmaceuticals Inc

Loss

993.57M

SYRE.O

Spyre Therapeutics Inc

9960.12

996.01M

PRAX.O

Praxis Precision Medicines Inc

Performance Decomposition

Market capitalization of ATAI increased by 294.83% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -2.13 to -6.66.

The secondary factor is the Revenue Growth, contributed 163.37%to the performance.

Overall, the performance of ATAI in the past 1 year is driven by P/E Change. Which is more unsustainable.

163.37%

273.00K → 719.00K

Revenue Growth

-81.64%

-21.01K → -3.86K

Margin Expansion

213.10%

-2.13 → -6.66

P/E Change

294.83%